Return to homepagePandemic Pact

Th1 / Th2 / Th17 / Treg response and TLRs / KIR receptors in clinical evolution of COVID19

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_01304

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    ALEJANDRO VALLEJO TILLER

  • Research Location

    Spain

  • Lead Research Institution

    Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBIO)

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The immune response is crucial in patients from day 5-7 of symptom evolution. At that time, certain patients unleash an exaggerated immune response that aggravates their clinical situation (cytokine storm), while others progress without known cause. Being able to analyze the Th1, Th2, Treg and Th17 response in these patients upon admission could have a predictive value of later severity of the disease. An exacerbated activation of the Th1 response and low Th2 could produce that described cytokine storm. The Treg and Th17 response could also modulate this response. In parallel, the initial control of SARS-CoV-2 infection is also limited by the expression of Toll-like receptors (TLRs) expressed on monocytes and dendritic cells (TLR-7 and TLR-8). Also, the KIR receptors on NK cells are important for the clearance of viral infections.